322 related articles for article (PubMed ID: 28940304)
1. The FOXA2 transcription factor is frequently somatically mutated in uterine carcinosarcomas and carcinomas.
Le Gallo M; Rudd ML; Urick ME; Hansen NF; ; Merino MJ; Mutch DG; Goodfellow PJ; Mullikin JC; Bell DW
Cancer; 2018 Jan; 124(1):65-73. PubMed ID: 28940304
[TBL] [Abstract][Full Text] [Related]
2. The genetic landscape of metaplastic breast cancers and uterine carcinosarcomas.
Moukarzel LA; Ferrando L; Da Cruz Paula A; Brown DN; Geyer FC; Pareja F; Piscuoglio S; Papanastasiou AD; Fusco N; Marchiò C; Abu-Rustum NR; Murali R; Brogi E; Wen HY; Norton L; Soslow RA; Vincent-Salomon A; Reis-Filho JS; Weigelt B
Mol Oncol; 2021 Apr; 15(4):1024-1039. PubMed ID: 33021035
[TBL] [Abstract][Full Text] [Related]
3. Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses.
Kuhn E; Wu RC; Guan B; Wu G; Zhang J; Wang Y; Song L; Yuan X; Wei L; Roden RB; Kuo KT; Nakayama K; Clarke B; Shaw P; Olvera N; Kurman RJ; Levine DA; Wang TL; Shih IeM
J Natl Cancer Inst; 2012 Oct; 104(19):1503-13. PubMed ID: 22923510
[TBL] [Abstract][Full Text] [Related]
4. Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial-mesenchymal transition.
Zhao S; Bellone S; Lopez S; Thakral D; Schwab C; English DP; Black J; Cocco E; Choi J; Zammataro L; Predolini F; Bonazzoli E; Bi M; Buza N; Hui P; Wong S; Abu-Khalaf M; Ravaggi A; Bignotti E; Bandiera E; Romani C; Todeschini P; Tassi R; Zanotti L; Odicino F; Pecorelli S; Donzelli C; Ardighieri L; Facchetti F; Falchetti M; Silasi DA; Ratner E; Azodi M; Schwartz PE; Mane S; Angioli R; Terranova C; Quick CM; Edraki B; Bilgüvar K; Lee M; Choi M; Stiegler AL; Boggon TJ; Schlessinger J; Lifton RP; Santin AD
Proc Natl Acad Sci U S A; 2016 Oct; 113(43):12238-12243. PubMed ID: 27791010
[TBL] [Abstract][Full Text] [Related]
5. Exome sequencing of serous endometrial tumors identifies recurrent somatic mutations in chromatin-remodeling and ubiquitin ligase complex genes.
Le Gallo M; O'Hara AJ; Rudd ML; Urick ME; Hansen NF; O'Neil NJ; Price JC; Zhang S; England BM; Godwin AK; Sgroi DC; ; Hieter P; Mullikin JC; Merino MJ; Bell DW
Nat Genet; 2012 Dec; 44(12):1310-5. PubMed ID: 23104009
[TBL] [Abstract][Full Text] [Related]
6. Somatic mutation profiles of clear cell endometrial tumors revealed by whole exome and targeted gene sequencing.
Le Gallo M; Rudd ML; Urick ME; Hansen NF; Zhang S; ; Lozy F; Sgroi DC; Vidal Bel A; Matias-Guiu X; Broaddus RR; Lu KH; Levine DA; Mutch DG; Goodfellow PJ; Salvesen HB; Mullikin JC; Bell DW
Cancer; 2017 Sep; 123(17):3261-3268. PubMed ID: 28485815
[TBL] [Abstract][Full Text] [Related]
7. PPP2R1A mutations are common in the serous type of endometrial cancer.
Nagendra DC; Burke J; Maxwell GL; Risinger JI
Mol Carcinog; 2012 Oct; 51(10):826-31. PubMed ID: 21882256
[TBL] [Abstract][Full Text] [Related]
8. Fbxw7 is a driver of uterine carcinosarcoma by promoting epithelial-mesenchymal transition.
Cuevas IC; Sahoo SS; Kumar A; Zhang H; Westcott J; Aguilar M; Cortez JD; Sullivan SA; Xing C; Hayes DN; Brekken RA; Bae-Jump VL; Castrillon DH
Proc Natl Acad Sci U S A; 2019 Dec; 116(51):25880-25890. PubMed ID: 31772025
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathological analysis of endometrial carcinomas harboring somatic POLE exonuclease domain mutations.
Hussein YR; Weigelt B; Levine DA; Schoolmeester JK; Dao LN; Balzer BL; Liles G; Karlan B; Köbel M; Lee CH; Soslow RA
Mod Pathol; 2015 Apr; 28(4):505-14. PubMed ID: 25394778
[TBL] [Abstract][Full Text] [Related]
10. Integrated Molecular Characterization of Uterine Carcinosarcoma.
Cherniack AD; Shen H; Walter V; Stewart C; Murray BA; Bowlby R; Hu X; Ling S; Soslow RA; Broaddus RR; Zuna RE; Robertson G; Laird PW; Kucherlapati R; Mills GB; ; Weinstein JN; Zhang J; Akbani R; Levine DA
Cancer Cell; 2017 Mar; 31(3):411-423. PubMed ID: 28292439
[TBL] [Abstract][Full Text] [Related]
11. Mutational analysis of the tyrosine kinome in serous and clear cell endometrial cancer uncovers rare somatic mutations in TNK2 and DDR1.
Rudd ML; Mohamed H; Price JC; O'Hara AJ; Le Gallo M; Urick ME; ; Cruz P; Zhang S; Hansen NF; Godwin AK; Sgroi DC; Wolfsberg TG; Mullikin JC; Merino MJ; Bell DW
BMC Cancer; 2014 Nov; 14():884. PubMed ID: 25427824
[TBL] [Abstract][Full Text] [Related]
12. Molecular Genetics of Endometrial Carcinoma.
Bell DW; Ellenson LH
Annu Rev Pathol; 2019 Jan; 14():339-367. PubMed ID: 30332563
[TBL] [Abstract][Full Text] [Related]
13. Pathologic and molecular features of uterine carcinosarcomas.
Lopez-Garcia MA; Palacios J
Semin Diagn Pathol; 2010 Nov; 27(4):274-86. PubMed ID: 21309261
[TBL] [Abstract][Full Text] [Related]
14. Histotype-genotype correlation in 36 high-grade endometrial carcinomas.
Hoang LN; McConechy MK; Köbel M; Han G; Rouzbahman M; Davidson B; Irving J; Ali RH; Leung S; McAlpine JN; Oliva E; Nucci MR; Soslow RA; Huntsman DG; Gilks CB; Lee CH
Am J Surg Pathol; 2013 Sep; 37(9):1421-32. PubMed ID: 24076778
[TBL] [Abstract][Full Text] [Related]
15. The mutational spectrum of FOXA2 in endometrioid endometrial cancer points to a tumor suppressor role.
Smith B; Neff R; Cohn DE; Backes FJ; Suarez AA; Mutch DG; Rush CM; Walker CJ; Goodfellow PJ
Gynecol Oncol; 2016 Nov; 143(2):398-405. PubMed ID: 27538367
[TBL] [Abstract][Full Text] [Related]
16. Functional characterization of recurrent FOXA2 mutations seen in endometrial cancers.
Neff R; Rush CM; Smith B; Backes FJ; Cohn DE; Goodfellow PJ
Int J Cancer; 2018 Dec; 143(11):2955-2961. PubMed ID: 30091462
[TBL] [Abstract][Full Text] [Related]
17. PP2A and E3 ubiquitin ligase deficiencies: Seminal biological drivers in endometrial cancer.
Gonzalez-Bosquet J; Bakkum-Gamez JN; Weaver AL; McGree ME; Dowdy SC; Famuyide AO; Kipp BR; Halling KC; Couch FJ; Podratz KC
Gynecol Oncol; 2021 Jul; 162(1):182-189. PubMed ID: 33867147
[TBL] [Abstract][Full Text] [Related]
18. Defective DNA mismatch repair and XRCC2 mutation in uterine carcinosarcomas.
Taylor NP; Gibb RK; Powell MA; Mutch DG; Huettner PC; Goodfellow PJ
Gynecol Oncol; 2006 Jan; 100(1):107-10. PubMed ID: 16169065
[TBL] [Abstract][Full Text] [Related]
19. Molecular alterations of PIK3CA in uterine carcinosarcoma, clear cell, and serous tumors.
Bashir S; Jiang G; Joshi A; Miller C; Matrai C; Yemelyanova A; Caputo TA; Holcomb KM; Ellenson LH; Gupta D
Int J Gynecol Cancer; 2014 Sep; 24(7):1262-7. PubMed ID: 25078343
[TBL] [Abstract][Full Text] [Related]
20. DNA Mismatch Repair-deficient Endometrial Carcinosarcomas Portend Distinct Clinical, Morphologic, and Molecular Features Compared With Traditional Carcinosarcomas.
Segura SE; Pedra Nobre S; Hussein YR; Abu-Rustum NR; Weigelt B; Soslow RA; DeLair DF
Am J Surg Pathol; 2020 Nov; 44(11):1573-1579. PubMed ID: 32804882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]